Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13390515 | 0.82 | NR1H2 (0.39) | TSHRSMN1; SMN2 | |
| SCHEMBL13390653 | 0.82 | NR1H2 (0.39) | TSHRSMN1; SMN2 | |
| SCHEMBL4000895 | 0.82 | NR1H2 (0.39) | TSHRSMN1; SMN2 | |
| SCHEMBL13390649 | 0.82 | NR1H2 (0.39) | TSHRSMN1; SMN2 | |
| SCHEMBL2795285 | 0.79 | TSHR (0.41) | TSHRHCRTR2 | |
| SCHEMBL29246084 | 0.78 | SMN1; SMN2 (0.39) | TSHRSMN1; SMN2 | |
| SCHEMBL28500620 | 0.78 | SMN1; SMN2 (0.39) | TSHRSMN1; SMN2 | |
| SCHEMBL29246082 | 0.78 | SMN1; SMN2 (0.39) | TSHRSMN1; SMN2 | |
| SCHEMBL13733872 | 0.77 | KDM4E (0.37) | — | |
| SCHEMBL23248453 | 0.76 | AGTR2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093706-A1 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PREXA PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| EP-2069300-A2 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PREXA PHARMACEUTICALS, INC. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008024371-A2 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PREXA PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093706-A1 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | SLC6A4, SLC18A2, SLC6A2 | TSHR 3227/4885HCRTR2 137/4885SMN1; SMN2 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.